Patent ID: 8415332

Claim:
A pharmaceutical kit comprising 83 to 89 daily dosages in sequential order for administration in at least three phases, each daily dosage comprising estrogen and progestin, wherein the daily dosage of estrogen in the first phase is equivalent to 15 μg to 25 μg of ethinyl estradiol, the daily dosage of estrogen in the second phase is equivalent to 20 μg to 30 μg of ethinyl estradiol, and the daily dosage of estrogen in the third phase is equivalent to 25 μg to 35 μg of ethinyl estradiol, wherein the daily dosage of estrogen in the second phase is higher than the daily dosage of estrogen in the first phase, and wherein the dosage of estrogen in the third phase is higher than the daily dosage of estrogen in the second phase.